Synapse Open Synapse
Biology

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

STAT News · · 1 min read

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.

Latest from STAT News